T Cell
A topic on our watch list — we track its coverage across 6 domains, including Aging Longevity, Chemicals and KRAS Research.
Coverage of T Cell is newly on the wire: 6 signals on the latest tracked day, level with its three-week baseline of 6, across 6 domains. That makes it the #327 most-covered of the 334 concerns we track.
If T Cell matters to your work, it just crossed our flagging thresholds — early and thin history, so watch whether the next few days confirm the move or fade it.
What’s changed
- CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial · GEN - Genetic Engineering & Biotechnology News · 2026-08-31
- Targeting a candidate stromal immune checkpoint: a cellular senescence signature identifies COMP⁺ cancer-associated fibroblasts associated with CD8⁺ T-cell exclusion via a predicted COMP-CD47 axis in colorectal cancer. · J Adv Res · 2026-08-20
- Akkermansia muciniphila supports anti-PD-1 therapy in colorectal cancer: Butyrate-associated metabolic changes and CD8⁺ T-cell responses. · Pathol Res Pract · 2026-08-17
- Cancer Drug Reduces SIV Reservoir in Macaques, May Inform HIV Cure Strategies · GEN - Genetic Engineering & Biotechnology News · 2026-09-04
- Immune System Signatures Correlate with the Near Term Risk of Developing Atherosclerosis · Fight Aging! · 2026-09-02
- AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial · Fierce Biotech · 2026-09-03 · usually covers Pharma Pipeline
What the reporting says
It shows up alongside Immunotherapy (23), Colorectal Cancer (18), CAR-T (11), KRAS (8).
Two steps out: Abstract (through Immunotherapy, 23 shared stories on the weaker link); FDA (through Immunotherapy, 23 shared stories on the weaker link); Lung Cancer (through Immunotherapy, 23 shared stories on the weaker link); Merck (through Immunotherapy, 23 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 24 separate days — concentrated in Pubmed Targeted and Oncology.